We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Getein Biotech, Inc.

Getein Biotech, Inc. is a fully integrated in vitro diagnostic company that develops, manufactures and distributes an... read more Featured Products: More products

Download Mobile App





Getein Biotech Demonstrates Rapid Immunofluorescence Quantitative Analyzers for POC Testing

By LabMedica International staff writers
Posted on 25 Jul 2023

Getein Biotech, Inc. More...

(Nanjing, China) is showcasing its latest innovations at AACC 2023 including its benchtop immunofluorescence and hematology analyzers as well as its handheld POCT analyzers.

At AACC 2023, Getein is demonstrating the Metis 600 integrated system that provides a suitable solution for immunofluorescence and hematology testing to low-volume laboratories. The combination of immunofluorescence and hematology methodologies in a single system allows for more comprehensive test items to be offered. Metis 600 improves laboratory efficiency through the highest level of automation and accelerates turnaround time for high-volume sample testing. Also on display is the MAGICL 6000 chemiluminescence immunoassay analyzer, a compact and innovative system offering an optimal choice for mid to high-workflow laboratories that need a one-step chemiluminescence solution. Highly productive and compact, this instrument enables fully automated operation and provides the fastest testing speed of any device of its size.

In addition, the company is demonstrating the Getein 1160 immunofluorescence quantitative analyzer - a multi-channel POCT analyzer with four incubation channels and one emergency test channel. It also has a constant test environment with 32℃ to ensure more accurate test results, making it ideal for applications in emergency, critical care (ICU, CCU), outpatient, cardiology, inpatient wards, clinical laboratories, etc. Alongside this, the company is demonstrating the Getein 1100 immunofluorescence quantitative analyzer that is used to measure the concentration of biomarkers in human whole blood, serum, plasma, urine, nasal swab, or saliva samples. The results can be used as an aid in clinical diagnostics of laboratory and point-of-care testing. In addition, Getein is showcasing the CM-400 fully automated clinical chemistry analyzer that is intended to quantitatively analyze chemical components in human serum, plasma, whole blood, urine, and cerebrospinal liquid samples, offering constant throughput of 400 T/h.

Related Links:
Getein Biotech, Inc. 


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.